Skip to content

Study · Animal study (in vivo) · new zealand white rabbit · 2017

11 results

Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide.

Zebaze R, Takao-Kawabata R, Peng Y, Zadeh AG, Hirano K, Yamane H, Takakura A, Isogai Y, Ishizuya T, Seeman E

Bone18 Mar 2017Cited by 39 (Europe PMC)

PMID28323145 (opens in a new tab)DOI10.1016/j.bone.2017.03.042 (opens in a new tab)PepBankPUB-28323145
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, total cross-sectional area did not differ between teriparatide regimens and control.

    In plain wordsIn rabbits, total cross-sectional area did not differ between teriparatide regimens and control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTotal cross-sectional area
    Study

    New Zealand white rabbitn = 17

    Proximal femur cortical bone
    Comparator
    All study groups
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    There was no difference in total, compact or transitional zone cross sectional areas between the groups.
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, compact cortex cross-sectional area did not differ between teriparatide regimens and control.

    In plain wordsIn rabbits, compact cortex cross-sectional area did not differ between teriparatide regimens and control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCompact cortex cross-sectional area
    Study

    New Zealand white rabbitn = 17

    Proximal femur cortical bone
    Comparator
    All study groups
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    There was no difference in total, compact or transitional zone cross sectional areas between the groups.
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, transitional zone cross-sectional area did not differ between teriparatide regimens and control.

    In plain wordsIn rabbits, transitional zone cross-sectional area did not differ between teriparatide regimens and control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTransitional zone cross-sectional area
    Study

    New Zealand white rabbitn = 17

    Proximal femur cortical bone
    Comparator
    All study groups
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    There was no difference in total, compact or transitional zone cross sectional areas between the groups.
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, daily teriparatide regimens increased the proportion of porosity attributable to larger pores versus control.

    In plain wordsIn rabbits, daily teriparatide increased the share of porosity from larger pores versus control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePorosity from larger pores
    Study

    New Zealand white rabbitn = 10

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 and 40μg/kg daily · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    The daily regimens were also associated with a greater proportion of porosity due to pores >15μm2
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, weekly teriparatide at the higher dose did not increase porosity versus control.

    In plain wordsIn rabbits, weekly teriparatide at the higher dose did not increase porosity versus control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePorosity
    Study

    New Zealand white rabbitn = 8

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    280μg/kg weekly · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    The 140 and 280μg/kg weekly were not associated with an increase in porosity.
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, daily low-dose teriparatide showed a nonsignificant increase in transitional zone porosity versus vehicle.

    In plain wordsIn rabbits, daily low-dose teriparatide did not significantly increase transitional zone porosity versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTransitional zone porosity
    Study

    New Zealand white rabbitn = 7

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20μg/kg daily · 1 monthAs given in this study (New Zealand white rabbit).

    Measurements

    Higher porosity
    3%
    20μg/kg daily
    p
    0.09
    versus control

    Source sentences

    Summary
    Compared to controls, the 20μg/kg daily was associated with 3.0% higher porosity in the transitional zone (p=0.09)
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, daily high-dose teriparatide increased cortical porosity versus vehicle.

    In plain wordsIn rabbits, daily high-dose teriparatide increased cortical porosity versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical porosity
    Study

    New Zealand white rabbitn = 7

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40μg/kg daily · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    while the 40μg/kg daily was associated with a higher porosity in the cortex (8.7%; p=0.04) and in the transitional zone (5.7%; p=0.007).
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, daily high-dose teriparatide increased transitional zone porosity versus vehicle.

    In plain wordsIn rabbits, daily high-dose teriparatide increased transitional zone porosity versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTransitional zone porosity
    Study

    New Zealand white rabbitn = 7

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40μg/kg daily · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    while the 40μg/kg daily was associated with a higher porosity in the cortex (8.7%; p=0.04) and in the transitional zone (5.7%; p=0.007).
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, low-dose daily teriparatide showed a nonsignificant twofold increase in transitional zone porosity from larger pores versus control.

    In plain wordsIn rabbits, low-dose daily teriparatide did not significantly increase transitional zone porosity from larger pores versus control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTransitional zone porosity from larger pores
    Study

    New Zealand white rabbitn = 7

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20μg/kg daily · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    The daily regimens were also associated with a greater proportion of porosity due to pores >15μm2; particularly in the transitional zone where 20 and 40μg/kg daily increased porosity 2 fold (p=0.06) and 5 fold (p=0.04) relative controls respectively.
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, high-dose daily teriparatide increased transitional zone porosity from larger pores versus control.

    In plain wordsIn rabbits, high-dose daily teriparatide increased transitional zone porosity from larger pores versus control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTransitional zone porosity from larger pores
    Study

    New Zealand white rabbitn = 7

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40μg/kg daily · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    The daily regimens were also associated with a greater proportion of porosity due to pores >15μm2; particularly in the transitional zone where 20 and 40μg/kg daily increased porosity 2 fold (p=0.06) and 5 fold (p=0.04) relative controls respectively.
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits, weekly teriparatide at the lower dose did not increase porosity versus control.

    In plain wordsIn rabbits, weekly teriparatide at the lower dose did not increase porosity versus control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePorosity
    Study

    New Zealand white rabbitn = 7

    Proximal femur cortical bone
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    140μg/kg weekly · 1 monthAs given in this study (New Zealand white rabbit).

    Source sentences

    Summary
    The 140 and 280μg/kg weekly were not associated with an increase in porosity.
    1 context sentence
    Summary · context
    We treated 17 female New Zealand white rabbits aged 6months for 1month with teriparatide [human PTH(1-34)] as follows. (i) Vehicle-treated Control (n=4); (ii) 20μg/kg daily (n=3); (iii) 40μg/kg daily (n=3); (iv) 140μg/kg weekly (n=3); (v) 280μg/kg weekly (n=4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.